Pestieau S R, Esquivel J, Sugarbaker P H
Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USA.
Ann Surg Oncol. 2000 Apr;7(3):199-203. doi: 10.1007/BF02523654.
Pseudomyxoma peritonei syndrome is a rare disease arising from perforation of an adenoma of the appendix. The syndrome is characterized by progressive accumulation of mucinous fluid and tumor within the abdomen and pelvis. Although this tumor is only superficially invasive and does not metastasize, it is a fatal disease. Extra-abdominal spread of pseudomyxoma peritonei is a rare occurrence, with few reports in the medical literature. This review focuses on pleural extension of mucinous tumor in patients with pseudomyxoma peritonei syndrome.
From December 1983 to April 1999, all patients who underwent cytoreductive surgery for pseudomyxoma peritonei syndrome were assessed for pleural involvement at the time of the presentation or follow-up. Clinical information on these patients, including chest computed tomographic scan, was retrospectively reviewed. The mechanisms of extension of mucinous tumor from peritoneal cavity to pleural surface and the results of treatment were of special interest.
Twenty-three of 426 patients (5.4%) showed pleural extension of pseudomyxoma peritonei syndrome. In four patients (17%), extension into the chest occurred before cytoreductive surgery. In 18 patients, the pleural space was entered during a subdiaphragmatic peritonectomy; and, in 12 patients, extension of disease from peritoneal to pleural space occurred. In six patients (26%), surgical interventions were required to excise tumor that had invaded the hemidiaphragm; and, in the six other patients (26%), there was a minor penetration during subphrenic peritonectomy, which was closed immediately. Finally, in seven patients (30%), the mechanism of spread was unknown. Twelve patients were treated for pleural thoracotomy. Eight patients had an attempt to completely eradicate pleural mucinous tumor, and five patients are currently disease free in the chest (22%); four of these five had intrapleural cytoreduction plus intrapleural chemotherapy. The median survival for all 23 patients is 55 months.
Pleural spread of pseudomyxoma peritonei syndrome may be a direct result of cytoreductive surgery and the subphrenic peritonectomy procedure. In some patients, dissecting mucinous tumor may infiltrate through the diaphragm and result in pleural extension. Pleural extension of pseudomyxoma peritonei syndrome carries a poor prognosis. Intrapleural chemotherapy combined with cytoreductive surgery may be of considerable value in treatment and prevention of disease dissemination; it should be considered when pleural extension of mucinous tumor is feared or confirmed at the time of cytoreductive surgery.
腹膜假黏液瘤综合征是一种源于阑尾腺瘤穿孔的罕见疾病。该综合征的特征是黏液性液体和肿瘤在腹部和盆腔内进行性积聚。尽管这种肿瘤仅为浅表浸润性且不发生转移,但却是一种致命疾病。腹膜假黏液瘤的腹外播散很少见,医学文献中报道较少。本综述聚焦于腹膜假黏液瘤综合征患者黏液性肿瘤的胸膜播散。
1983年12月至1999年4月,对所有接受腹膜假黏液瘤综合征减瘤手术的患者在就诊或随访时评估胸膜受累情况。回顾性分析这些患者的临床资料,包括胸部计算机断层扫描。特别关注黏液性肿瘤从腹腔扩展至胸膜表面的机制及治疗结果。
426例患者中有23例(5.4%)出现腹膜假黏液瘤综合征的胸膜播散。4例患者(17%)在减瘤手术前即已出现胸膜播散。18例患者在膈下腹膜切除术中进入胸膜腔;12例患者疾病从腹腔扩展至胸膜腔。6例患者(26%)需要手术切除侵犯半膈肌的肿瘤;另外6例患者(26%)在膈下腹膜切除术中出现轻微穿透,立即进行了缝合。最后,7例患者(30%)的播散机制不明。12例患者接受了胸膜切开术治疗。8例患者试图完全清除胸膜黏液性肿瘤,5例患者目前胸部无疾病(22%);这5例患者中有4例接受了胸膜内减瘤术加胸膜内化疗。23例患者的中位生存期为55个月。
腹膜假黏液瘤综合征的胸膜播散可能是减瘤手术和膈下腹膜切除术的直接结果。在一些患者中,分离黏液性肿瘤可能会浸润膈肌并导致胸膜播散。腹膜假黏液瘤综合征的胸膜播散预后较差。胸膜内化疗联合减瘤手术在治疗和预防疾病播散方面可能具有重要价值;在减瘤手术时若担心或证实存在黏液性肿瘤的胸膜播散,应考虑采用该方法。